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REVIEW
Unleashing endogenous TNF-alpha 
as a cancer immunotherapeutic
Steven F. Josephs1, Thomas E. Ichim2, Stephen M. Prince1*, Santosh Kesari3, Francesco M. Marincola1, 
Anton Rolando Escobedo4 and Amir Jafri1
Abstract 
Tumor necrosis factor (TNF)-alpha was originally identified in the 1970s as the serum mediator of innate immunity 
capable of inducing hemorrhagic necrosis in tumors. Today, a wide spectrum of biological activities have been 
attributed to this molecule, and clinical translation has mainly occurred not in using it to treat cancer, but rather to 
inhibit its effects to treat autoimmunity. Clinical trials utilizing systemic TNF-alpha administration have resulted in an 
unacceptable level of toxicities, which blocked its development. In contrast, localized administration of TNF-alpha in 
the form of isolated limb perfusion have yielded excellent results in soft tissue sarcomas. Here we describe a novel 
approach to leveraging the potent antineoplastic activities of TNF-alpha by enhancing activity of locally produced 
TNF-alpha through extracorporeal removal of soluble TNF-alpha receptors. Specifically, it is known that cancerous 
tissues are infiltrated with monocytes, T cells, and other cells capable of producing TNF-alpha. It is also known that 
tumors, as well as cells in the tumor microenvironment produce soluble TNF-alpha receptors. The authors believe 
that by selectively removing soluble TNF-alpha receptors local enhancement of endogenous TNF-alpha activity may 
provide for enhanced tumor cell death without associated systemic toxicities.
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Background
The history of TNF-alpha is very closely related to the 
history of tumor immunotherapy. In the early 1900s, the 
New York physician William Coley observed that various 
cancer patients would enter remission after experienc-
ing bacterial infections. In a brave set of experiments, Dr. 
Coley began emulating bacterial infections by purposely 
administering various combinations of pathogens to 
patients. One of these mixtures, containing Streptococcus 
pyogenes and Serratia marcescens, was demonstrated to 
possess therapeutic activity and became widely used in 
the USA prior to the advent of chemotherapy and radio-
therapy. Today, such “Coley’s toxins” are limited due to 
lack of controlled clinical trials and FDA approvals. In the 
1960s, attempts to identify the molecular mechanisms 
by which Serratia marcescens induced tumor regression 
led to the discovery of a “factor” in the sera of treated 
mice [1]. This factor was identified in 1975 as “Tumor 
Necrosis Factor” (TNF-alpha) [2]. It was found that this 
endotoxin induced factor, was also inducible with known 
immune stimulants such as bacillus Calmette–Guerin 
(BCG), zymosan, and Corynebacteria. The isolated factor 
had the capability to directly kill tumor cells in vitro, but 
there were no deleterious effects on proliferating non-
malignant murine embryonic cells.
Molecular analysis led to cloning of the cDNA and 
revealed the molecule was comprised of 233 amino 
acids with a leader sequence of the first 76 amino acids 
[3, 4]. Interestingly, it was found that the same sequence 
belonged to another factor associated with cancer: 
Cachectin [5]. Cachectin was originally demonstrated to 
mediate weight loss and alter normal metabolic priorities 
through its effects on both the central nervous system 
(CNS) and peripheral tissues. Early studies showed that 
administration of cachectin in animals induces cachexia 
with a pattern of tissue wasting that includes whole-body 
protein depletion, unlike the protein-conserving pat-
tern induced by simple caloric restriction [6, 7]. Given 
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the inflammatory nature of TNF-alpha, studies where 
performed to assess its role in endotoxin-induced shock 
models.
It was found that administration of TNF-alpha in 
quantities approximating endogenous levels that were 
observed in response to endotoxin resulted in hypoten-
sion, metabolic acidosis, hemoconcentration, and death 
due to respiratory arrest within minutes to hours. This 
sequence resembled sepsis associated symptomology. 
Hyperglycemia and hyperkalemia were also observed 
after infusion. At necropsy, diffuse pulmonary inflam-
mation and hemorrhage were apparent on gross and 
histopathologic examination, along with ischemic and 
hemorrhagic lesions of the gastrointestinal tract, and 
acute renal tubular necrosis [8–11]. Thus TNF-alpha, 
appeared to not only be a potent mediator of tumor 
regression, but also an effector of cachexia, and a con-
tributor to one of the main mechanisms leading to septic 
shock.
TNF‑alpha forms and family
TNF-alpha is found in a soluble and membrane bound 
form. The soluble plasma form of TNF-alpha is cleaved 
from the membrane forms by a metalloproteinase termed 
TNF-alpha-converting enzyme (TACE) which belongs to 
the ADAMs family of disintegrins [12, 13]. Soluble TNF-
alpha is 17-kDa protein consisting of 157 amino acids 
that forms a homotrimer for receptor activation. TNF-
alpha is mainly produced by activated macrophages, T 
lymphocytes, and natural killer (NK) cells [14]. A related 
but distinct cytokine, TNF-beta, previously known as 
Lymphotoxin was characterized to share some of the 
activity of TNF-alpha [15–17]. At present count, there 
are 19 members of the TNF family and 29 receptors that 
have been characterized [18–20].
TNF‑alpha receptors 1 and 2
The activity of TNF-alpha is mediated through two cell 
surface receptors, TNF-R1 (p55) and TNF-R2 (p75) that 
differ in their signaling activity. TNF-R1 is usually pro-
apoptotic whereas TNF-R2 is usually anti-apoptotic 
[21]. TNF-R1 and TNF-R2 have similar extracellular 
TNF-binding structures characterized by four repeated 
cysteine-rich domains but have different intracellular 
domains [22]. The main structural difference between 
TNF-R1 and TNF-R2 that accounts for their divergent 
biological activity resides in that TNF-R2 lacks an intra-
cellular death domain. Thus, in many systems, TNF-
alpha promotes apoptosis through activating TNF-R1 
but causes pro-survival signaling through TNF-R2 
[23–28]. After binding TNF-alpha, TNF-R1 recruits 
the adaptor protein TNF-R1-associated death domain 
protein (TRADD) and its downstream caspases (i.e. 
Caspase 8) causing apoptosis [18, 29, 30]. Conversely, 
when TNF-alpha activates TNF-R2, recruitment of 
the TNF receptor-associated factors (TRAF2) occurs, 
resulting in stimulation of NF-kappa B, which possesses 
anti-apoptotic properties [19, 31]. TNF-R1 is the high 
affinity receptor which is internalized upon ligation 
whereas TNF-R2 is shed [32]. TNF-R2 is known to pos-
sess a higher affinity towards membrane bound TNF-
alpha as compared to soluble TNF-alpha [33].
While TNF-R1 is expressed on various tumor cells 
[34], and tumor endothelial cells [35], TNF-R2 is 
expressed on various immune cells including T regu-
latory cells [36, 37], myeloid suppressor cells [38], and 
some cancer cells [39, 40]. That TNF-R1 receptor is 
mainly responsible for the toxicity is demonstrated by 
its reduction by treating with antisense TNF-R1 [41]. 
Tumor resistance to the cytotoxic effects of TNF-alpha 
is mediated by TNF-R2. For example, in the Lewis Lung 
Model, knock down of TNF-R2 in the cancer cells pro-
motes robust anti-tumor effects upon administration 
of low dose murine TNF-alpha whereas in wild type 
mice it enhanced tumor growth while the TNF-R1 
knockdown was not affected [42]. Moreover, TNF-R2 
activation has been implicated in T-reg expansion and 
immune-suppression [28, 43].
Role of TNF receptors in cancer
The effects of systemically administered TNF-alpha are 
blocked by soluble receptors, sTNF-R1 and sTNF-R2, 
that are released into the plasma [44]. These are cleaved 
from the membrane forms by TACE (ADAM17) upon 
the introduction or release of soluble TNF-alpha [45–
47]. The receptor ligand affinity is largely dependent on 
the adaptor protein recruitment [48]. However TNF-
alpha mutants have been developed that specifically 
bind either TNF-R1 or TNF-R2 [49] and novel mutants 
have been obtained with lower toxicity and increased 
anti-tumor activity compared to wild type TNF-alpha 
[50].
The concentration of the soluble receptors increases 
following exposure to TNF that is produced after infec-
tions or upon administration of recombinant TNF as a 
function of the natural TNF buffering system to control 
runaway cytokine response [47]. These receptors have 
been found to be elevated in tumors and in the plasma 
of cancer patients [51] as a mechanism of tumor survival 
by counteracting the anti-cancer potential of TNF-alpha 
[52, 53]. Various complex interplays between receptors 
have been described based on vitro studies, which in 
some cases are contradictory. Accordingly, we will dis-
cuss below the cellular effects of TNF-alpha in various 
immunological and cancer systems.
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Cellular effects of TNF‑alpha
Approximately 28% of cancers are susceptible to direct 
cell killing mediated by soluble TNF. The anti-tumor 
activity of TNF-alpha is now well established and can be 
mediated through a variety of mechanisms including: (1) 
Cellular apoptosis by binding to tumor cell surface recep-
tors; (2) T-effector cell activation (macrophage and NK 
cells) by blocking T-Reg cells that are immune suppres-
sors [54, 55]; (3) Inducing tumor microvasculature col-
lapse through endothelial cell modulation and disruption 
of neoangiogenesis including disruption of tumor vas-
culature [56, 57]; (4) Promoting TAM (tumor associated 
macrophages) to M1 anti-tumor stage (see Fig.  1); (5) 
Attraction and stimulation of neutrophils and monocytes 
to sites of activation for anti-tumor immune responses 
[58, 59]; and (6) Downregulation of IL-13 expression by 
eosinophilic-like cells and inhibition of tumor induced 
monocyte differentiation to immunosuppressive pheno-
types [60].
As the most pleiotropic of cytokines, TNF-alpha con-
tributes to both inflammation during infections and 
anti-inflammatory/tissue repair processes after clear-
ance of infections [61]. Its effects at low levels of expres-
sion contribute to tumorigenesis [62]. Upon exposure 
to inflammatory stimuli, TNF-alpha as well as IL-1 and 
other chemokines are produced mainly by activated mac-
rophages and other cells of the myeloid lineage which 
attracts and activates neutrophils and monocytes to the 
tumor site. In tumors, the membrane form of TNF-alpha 
on tumor cells interacts mainly with TNF-R2 to activate 
clearance of pro-tumor suppressor cells via the produc-
tion of reactive oxygen intermediates with signaling 
through ceramide [63]. Consequently, intratumoral pres-
ervation of the membrane form (with lower intratumoral 
TACE activity) is associated with better prognosis [64]. 
Reverse signaling can also occur where the receptors 
can activate intracellular processes after binding to the 
membrane form of TNF-alpha [65]. Neither TNF-alpha 
nor its receptors are lethal in murine knockout models. 
However, the organization of the lymphoid organs and 
thymus function are affected [66].
The anti-tumor effects of TNF-alpha have been dem-
onstrated on primary tumors with significant pancancer 
effects through vascular destruction and tumor necrosis 
[56]. This effect is mainly attributable to TNF-R1 liga-
tion. However, minimal residual disease (MRD) may be 
stimulated upon infections and lead to the development 
of resistance to cytotoxic drugs [67]. In a murine model, 
treatment with anti-TNF antibodies delays the onset of 
recurrence after initial complete regression of primary 
tumors. In attempt to control the potential pro-tumor 
effects of TNF-alpha, human clinical trials were con-
ducted using anti-TNF antibodies or receptors and these 
have met with limited disease stabilization in approxi-
mately 20% of the patients [68–70]. However, induction 
of lymphoma or skin cancer was also observed [71, 72]. 
The ability to specifically block the anti-inflammatory/
tissue repair processes of TNF-alpha in MRD would be 
of significance with respect to controlling the recurrence 
of tumors. An elegant approach would be to identify 
methods with cytokine or drug combinations that induce 
long-term immune responses such as the combination of 
TNF and gamma Interferon [73]. Obviously, predicting 
outcomes will remain speculative until clinical trials are 
conducted.
Potential for general anti‑tumor therapy 
via vascular disruption by TNF
Tumors can be categorized into three major types regard-
ing their response to chemotherapy immune modula-
tors: “hot”, “cold” and “intermediate”. Hot tumors contain 
a plethora of cell infiltrates whereas cold tumors have 
relatively few. Intermediate tumors are types that fall in 
between. Clinically, hot tumors tend to respond well to 
therapy, whereas cold tumors are resistant. Intermediate 
tumors may respond at first but then become resistant to 
therapy.
With few exceptions, tumors are dependent on neo-
vascularization and in theory share a common suscepti-
bility to TNF induced vascular disruption. In sufficient 
amounts, the global effect of TNF is predictably rapid, 
dependent on pertussis toxin G-protein inhibition and 
stimulation of the release of protein S from the tumor 
endothelium to promote vascular modulation, and 
induces fibrin accumulation with clotting and enhance-
ment of permeability leading to necrosis [74]. This effect 
is dependent on C5a complement factor [75]. Of inter-
est is that specific delivery of TNF-alpha to tumor sites 
promotes anti-tumor effects [76, 77]. Overexpression of 
Fig. 1 Turning Cold Tumors Hot. TNF induces inflammation and 
anti-tumor M1. Soluble TNF receptors block the effects of TNF. 
Removal of sTNF-Rs unleashes TNF activity
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TNF in cancer cells results in longterm tumor growth 
suppression, independent of IL-12 or IL-18 and works 
via a STAT1 and IFN regulatory factor 1-dependent IFN-
gamma pathway [78]. Such higher-than-physiologic con-
centrations of TNF work through similar mechanisms in 
the normal vasculature leading to systemic toxicity. Fac-
tors in the tumor microenvironment contribute to the 
greater sensitivity of the tumor vasculature to TNF.
Clinical trials of TNF‑alpha for cancer therapy
Initial clinical trials of TNF-alpha utilized systemic 
administration. Phase 1 studies all reported sepsis-associ-
ated symptoms as dose-limiting toxicities [79]. For exam-
ple, Kimura et  al. administered intravenous infusions 
starting at 1 × 10 [5] units/m2 and escalated to 16 × 10 
[5] units/m2. Fever, rigors, nausea and vomiting, and ano-
rexia toxicities where found to be non-dose-dependent; 
whereas hypotension, leukocytosis, thrombocytopenia 
and transient elevation of transaminases (SGOT and 
SGPT) where dose-dependent. Disseminated intravas-
cular coagulopathy (DIC), a classical symptom of sepsis, 
was observed at the highest dose. The authors concluded 
that the maximum tolerated dose was 12 × 10 [5] units/
m2 [80]. Other studies found similar toxicities associated 
with systemic TNF-alpha administration, with little or no 
favorable achievement in tumor response [81–84]. Part 
of the cause of TNF-alphaassociated systemic toxicity is 
its ability to induce alterations to endothelial cells, result-
ing, in part, in augmentation of coagulopathy [85].
Given the inability to translate the profound anti-tumor 
effects observed in animal studies to human studies, 
some researchers have explored localized administration 
of TNF-alpha in hopes of avoiding adverse effects associ-
ated with systemic use. One of the first reports describing 
localized administration of TNF-alpha was Kahn et  al. 
who treated 27 patients suffering from Kaposi’s sarcoma. 
Intratumoral administration reduced the cross-sectional 
area in 15 of 16 injected cancer lesions and caused the 
complete disappearance of three lesions [86]. The noted 
high degree of vascularization in Kaposi’s sarcoma may 
be one of the explanations for the high degree of success, 
given that TNF-alpha is known to induce vascular hem-
orrhage in malignant tissues [87–89]. Multiple mecha-
nisms are believed to be associated with tumor vascular 
damage by TNF-alpha, including induction of release of 
von Willebrand Factor, which is a known anti-coagulant, 
as well as endothelial cell activation leading to thrombo-
sis [90].
One clinically successful utilization of localized TNF-
alpha therapy is its use (usually in combination with the 
alkylating agent melphalan) in isolated limb perfusion 
(ILP) protocols. Early studies demonstrated synergy 
between TNF-alpha and melphalan in animal models of 
ILP [91, 92]. These procedures have been translated to 
patients with melanoma and soft tissue sarcomas, where 
the complete response rate has been 80%. It is believed 
that there are two mechanisms by which TNF-alpha 
functions as a contributor to such high response rates. 
The first involves augmentation of endothelium perme-
ability, which facilitates entrance of chemotherapy, and 
the second mechanism involves direct killing of tumor 
endothelium, which results in vascular leakage. Hemor-
rhagic necrosis of tumors is observed in a rapid manner 
subsequent to TNF-alpha and melphalan administration, 
with disruption of cell–cell adhesive junctions occurring 
within minutes, followed by tumor vascular collapse 24 h 
later [58, 93]. From a clinical perspective TNF-alpha ILP 
therapy was approved in Europe for high grade soft tissue 
sarcoma in 1998 [94].
Another clinical success of localized TNF-alpha admin-
istration is in liver metastasis where isolated hepatic per-
fusion (IHP) may be performed. IHP was first clinically 
applied almost 50  years ago [95] and offered the ability 
to locally administer high concentrations of chemothera-
peutic agents without systemic toxicities. In extending 
IHP to TNF-alpha administration, one phase 2 trial at the 
Surgery Branch of the NCI, the overall response rate in 
50 patients was reported at 74% and was observed across 
virtually all types of histologies treated. The response 
rates were maintained even in patients who had numer-
ous metastases, large metastases, or who had a signifi-
cant percentage of liver replaced by tumor. Overall the 
duration of response was 9  months, although in some 
patients it was more than 3  years [95]. To assess the 
contribution of TNF-alpha versus melphalan alone, 22 
patients with ocular melanoma metastatic to liver were 
treated: 11 with melphalan alone, and 11 with TNF-alpha 
and melphalan. Patients possessed advanced tumor bur-
den with a mean percentage of hepatic replacement of 
25%. The overall response rate in 21 patients was 62% 
including 2 radiographic complete responses (9.5%) and 
11 partial responses (52%). The overall median duration 
of response was 9 months (range 5–50) and was signifi-
cantly longer in those treated with TNF than without (14 
versus 6  months, respectively). This study points to the 
importance of TNF-alpha in isolated perfusion proto-
cols [96]. Interestingly, in animal models of IHP, correla-
tions are seen between degree of tumor vascularization 
and tumor reduction, further suggesting that TNF-alpha 
mechanistically targets the tumor endothelium [97].
Extracorporeal removal of soluble TNF‑alpha 
receptors as a therapeutic
In the light of their pro-tumor activity, the removal of 
soluble TNF-Rs seemed to be a logical step toward the 
development of an effective anti-cancer therapy [52, 
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53]. To test the anti-cancer effects of removing inhibi-
tory sTNF-Rs, Immunicom, Inc. conducted a pre-
clinical canine cancer study using a novel single-chain 
TNF-alphabased affinity column (a.k.a. “LW-02” device) 
used in combination with a Terumo Optia apheresis 
system. The blood from catheterized canine patients 
was pumped into the Optia system which separated 
the patients’ plasma from their cells by continuous cen-
trifugation. During each treatment, an LW-02 affinity 
column device was placed into the plasma flow line to 
capture sTNF-Rs from the patient’s plasma which was 
then recombined with the previously separated cells and 
returned to the patient. Most of the dogs in the trial were 
stage III or IV patients which had failed standard thera-
peutic approaches. The results of the study were very 
encouraging.
Overall, 50–60% of the patients treated were observed 
to have either stable disease or partial responses by 
RECIST Criteria during treatment with one patient hav-
ing experienced a complete response with clearance of 
metastases. In over 300 treatments, throughout the study, 
the LW-02 devices appeared to be safe with no adverse 
events that were attributable to their use. The quality of 
life of the patients was effectively maintained during the 
treatment regimens and a significant life extension was 
observed based on initial prognoses.
In humans, few treatment options are available for 
stage IV patients that are unresponsive to standard treat-
ments. Thus, subtractive therapies may be an effective 
alternative to fill this gap.
There is also potential for its use: (1) In combina-
tion therapies with cytotoxic drugs that induce or are 
enhanced in combination TNF-alpha (Table 1); (2) With 
immunotherapeutics such as antibodies to PD1, PDL1 or 
CTLA4; and/or (3) In combination with cytokines, such 
as IFNg and TNF-alpha [73]. It is speculated that the 
removal of TNF receptors may increase the effectiveness 
of TNF-alpha administration while decreasing systemic 
toxicity.
Conclusion
TNF-alpha is a fundamental molecule in various aspects 
of immunology. Original efforts at therapeutic applica-
tions failed due to systemic toxicities. In the new era of 
cancer immunotherapy, a promising research direction is 
augmentation of endogenous TNF-alpha activity through 
removal of its soluble receptors.
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